市場調査レポート
商品コード
1492237
アトピー性皮膚炎市場:薬剤クラス別、投与経路別、流通チャネル別-世界予測2024-2030年Atopic Dermatitis Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable, Oral, Topical), Distribution Channel - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
アトピー性皮膚炎市場:薬剤クラス別、投与経路別、流通チャネル別-世界予測2024-2030年 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
|
アトピー性皮膚炎市場規模は2023年に63億8,000万米ドルと推計され、2024年には67億4,000万米ドルに達し、CAGR 5.88%で2030年には95億3,000万米ドルに達すると予測されています。
一般に湿疹として知られるアトピー性皮膚炎は、皮膚の乾燥、かゆみ、炎症を引き起こす慢性の皮膚疾患です。多くの場合、幼児期に発症し、成人期まで持続することもあれば、時間の経過とともに治癒することもあります。アトピー性皮膚炎を持つ個人の皮膚は、しばしばバリア機能が低下した徴候を示し、感染症や刺激に弱くなります。この病態の管理には、保湿、誘因の回避、処方された薬剤による症状および炎症のコントロールが一般的です。アトピー性皮膚炎のニーズは、乾燥肌、ひどいかゆみ、炎症性発疹を特徴とする症状の世界の有病率の増加とともに、著しく増加しています。また、先進国、新興国を問わず、国民の意識の高まりやヘルスケア支出の増大も市場拡大の大きな要因となっています。さらに、政府や医療機関の取り組みは、治療へのアクセスや購入しやすさを向上させる上で極めて重要です。しかし、先進的治療に伴う高額な費用が多くの患者のアクセスを制限する可能性があるなど、市場は課題に直面しています。また、地域によって異なる規制環境の複雑さも、製品の入手を妨げ、開発コストを膨れ上がらせる可能性があります。このような問題があるにもかかわらず、遠隔医療の導入は、特に遠隔患者管理のための重要な機会として浮上しており、それによってアトピー性皮膚炎治療を含むヘルスケア・サービスへのアクセシビリティが向上しています。さらに、個別化医療へのシフトは治療効果の向上を示し、この分野の患者ケアに革命をもたらす可能性があります。
主な市場の統計 | |
---|---|
基準年[2023] | 63億8,000万米ドル |
予測年[2024] | 67億4,000万米ドル |
予測年 [2030] | 95億3,000万米ドル |
CAGR(%) | 5.88% |
地域別の洞察
アトピー性皮膚炎治療の地域情勢は、ヘルスケアインフラ、患者の認知度、経済の多様性などの多様な要因の影響を受け、世界各地域で顕著なばらつきが見られます。南北アメリカでは、アトピー性皮膚炎に対する高い認識と確立されたヘルスケアの枠組みが、先進的な治療オプションの採用と継続的な医薬品の研究開発を支え、革新的な製剤や生物製剤を通じて患者の転帰を向上させています。欧州も同様の成長パターンを示しており、その強固なヘルスケア政策と、規制当局の承認を合理化するイニシアチブによって促進される最先端研究への重点的な取り組みによって、同様の成長パターンを示しています。中東とアフリカはヘルスケアの能力と意識が向上しており、アトピー性皮膚炎治療市場に新たな成長の可能性をもたらしています。アジア太平洋地域は、ヘルスケアへの投資が急増し、伝統的な治療法と近代的な医療行為の融合という独自の傾向を持つ、ダイナミックで急速に発展する市場です。先進的なヘルスケアシステムを持つ日本とオーストラリアは、皮膚科学の強力な研究部門に支えられ、治療導入の革新を続けています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、アトピー性皮膚炎市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、ビジネス戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、アトピー性皮膚炎市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、アトピー性皮膚炎市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[186 Pages Report] The Atopic Dermatitis Market size was estimated at USD 6.38 billion in 2023 and expected to reach USD 6.74 billion in 2024, at a CAGR 5.88% to reach USD 9.53 billion by 2030.
Atopic dermatitis, commonly known as eczema, is a chronic skin condition causing dry, itchy, and inflamed skin. It often starts in the early childhood and can persist into adulthood or resolve over time. The individual's skin with atopic dermatitis often shows signs of a compromised barrier, making it more susceptible to infections and irritants. Management of the condition typically involves moisturizing regimens, avoiding triggers, and using prescribed medications to control symptoms and inflammation. The need for atopic dermatitis is experiencing a significant increase, with an increasing global prevalence of the condition characterized by dry skin, severe itching, and inflamed rashes. The rising public awareness and augmented healthcare spending across both developed and developing nations are also considerable factors in the expansion of the market. Moreover, government and health organizations' initiatives are pivotal in enhancing treatment accessibility and affordability. However, the market faces challenges, such as the high costs associated with advanced treatments, which may restrict access for many patients. The complexity of regulatory environments across different regions can also hinder product availability and inflate development costs. Despite these issues, the incorporation of telemedicine has emerged as a key opportunity, particularly for remote patient management, thereby increasing the accessibility of healthcare services, including atopic dermatitis treatment. Additionally, the shift towards personalized medicine showcases enhancements in treatment efficacy, which could revolutionize patient care in this field.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.38 billion |
Estimated Year [2024] | USD 6.74 billion |
Forecast Year [2030] | USD 9.53 billion |
CAGR (%) | 5.88% |
Regional Insights
The geographical landscape for atopic dermatitis treatment displays pronounced variation across global regions, influenced by diverse factors such as healthcare infrastructure, patient awareness, and economic diversity. In the Americas, high awareness of atopic dermatitis and well-established healthcare frameworks support the adoption of advanced treatment options and ongoing pharmaceutical R&D, enhancing patient outcomes through innovative drug formulations and biologics. Europe displays similar growth patterns with its robust healthcare policies and an emphasis on cutting-edge research facilitated by initiatives that streamline regulatory approvals. The Middle East and Africa are advancing in healthcare capabilities and awareness, which significantly presents new growth avenues for the atopic dermatitis treatment market. The Asia-Pacific region showcases a dynamic and rapidly evolving market, with a surge in healthcare investment and a unique inclination towards integrating traditional remedies with modern medical practices. Japan and Australia, with their advanced healthcare system, continue to innovate treatment adoption, backed by strong research sectors in dermatology.
Market Insights
The market dynamics represent an ever-changing landscape of the Atopic Dermatitis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Atopic Dermatitis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Johnson & Johnson's Strategic Acquisition of Proteologix to Enhance Atopic Dermatitis and Asthma Treatment Options
Johnson & Johnson Services, Inc. has announced the acquisition of Proteologix, Inc., a biotechnology company focused on developing bispecific antibodies for immune-mediated diseases. The purchase, valued at USD 850 million in cash, along with potential additional milestone payments, aims to broaden Johnson & Johnson's immunology portfolio. Proteologix boasts pivotal assets, including PX128 and PX130, as well as bispecific antibodies targeting multiple cytokines associated with atopic dermatitis (AD) and asthma. PX128, which is expected to enter phase 1 development, targets both IL-13 and TSLP, central mediators in Th2 skin inflammation and tissue inflammation, respectively. [Published On: 2024-05-16]
Eli Lilly's Lebrikizumab Demonstrates Efficacy in Skin of Color for Atopic Dermatitis
Eli Lilly and Company announced positive results from a pioneering Phase 3 clinical study of lebrikizumab aimed at treating moderate-to-severe atopic dermatitis (AD) in individuals with skin of color. Unveiled at the American Academy of Dermatology Annual Meeting, this research marks a significant stride, focusing on patient demographics often underrepresented in clinical trials. The 16-week study showcased lebrikizumab's substantive efficacy in skin clearance and itch relief among 50 participants, which aligns with prior outcomes observed in broader Phase 3 trials, thus potentially positioning lebrikizumab as a leading biologic treatment post topical therapies across diverse skin tones. [Published On: 2024-03-10]
Glenmark and Pfizer Introduce New Atopic Dermatitis Treatment in India
Glenmark Pharmaceuticals Limited, in collaboration with Pfizer Inc., has launched a novel treatment for atopic dermatitis in India named Abrocitinib. This innovative oral medication is specifically designed to offer relief to patients suffering from moderate-to-severe forms of the condition. Abrocitinib's introduction into the Indian market represents a significant advancement, addressing the unmet needs of numerous patients whose daily lives are impacted by this chronic skin disease. [Published On: 2024-01-31]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Atopic Dermatitis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage